focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,785.50
Bid: 1,785.00
Ask: 1,786.00
Change: -27.00 (-1.49%)
Spread: 1.00 (0.056%)
Open: 1,792.50
High: 1,802.00
Low: 1,785.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Two votes cast to start BoE tapering

Thu, 23rd Sep 2021 12:08

(Alliance News) - Stock prices in London were slightly higher, even as both the US and UK central banks edged toward tapering economic stimulus.

The Monetary Policy Committee of the Bank of England voted by a majority of 7-2 to maintain quantitative easing at the current pace of GBP895 billion. Dave Ramsden and Michael Saunders cast dissenting votes to cut gilt QE to GBP840 billion. All 9 MPC members voted to keep interest rates unchanged, with the Bank Rate at 0.10%.

The pound was quoted at USD1.3674 on Thursday after the midday decision by the BoE, up from USD1.3659 at the London equities close Wednesday.

The FTSE 100 index was up 8.36 points, or 0.1%, at 7,091.71. The mid-cap FTSE 250 index was up 53.25 points, 0.2%, at 23,837.79. The AIM All-Share index was up 6.03 points, 0.5%, at 1,274.16.

The Cboe UK 100 index was up 0.2% at 705.40. The Cboe 250 was flat at 21,622.30. The Cboe Small Companies was 0.1% lower at 15,528.00.

In mainland Europe, the CAC 40 stock index in Paris and the DAX 40 index in Frankfurt were both up 0.8%.

Analysts at ActivTrades said investors welcomed Wednesday's policy statement from the US Fed. "[Chair] Jerome Powell confirmed tapering is on its way and will start sooner than expected. The Fed added it wouldn't need 'a very strong jobs report to go ahead with taper', which can be seen as a message to the market that the party will finally come to an end, mentioning November as a potentially good moment to scale back asset purchases.

"However, the market hasn't bought the rumour of any potential tapering to come but instead preferred to stick to the reality of the current extremely dovish environment that will remain for some time at least."

In the FTSE 100, Rolls-Royce was the best performer, up 3.4% at 126.26 pence after Berenberg raised its price target on the stock to 160p from 150p and reiterated its Buy rating.

Reckitt Benckiser was up 0.3%. The hygiene and home cleaning products firm said trading since its half-year results in July has been in line with management expectations.

Reckitt said it continued to be confident in delivering 2021 like-for-like net revenue growth in a range of 0% to 0.2% and an adjusted operating profit margin between 22.7% to 23.2%. Reckitt posted like-for-like net revenue growth of 12% and an adjusted operating profit margin of 23.6% for 2020.

Royal Mail shares were flat after the UK postal operator lifted its profit guidance and expressing confidence in its outlook.

In the five months to the end of August, total revenue grew by 8.2% year-on-year and by 18% compared to the same period in 2019.

In the domestic Royal Mail arm, revenue increased by 7.2% year-on-year and by 12% against the same period in 2019. The company said domestic parcel volumes are up by around third compared to pre-Covid levels and that it is maintaining its share of the UK market.

At its GLS international logistics unit, revenue rose 9.3% from the same time last year and by 31% versus the same period in 2019.

Looking ahead, Royal Mail expects adjusted operating profit for the six months to the end of September to be around GBP395 million to GBP400 million, with at least GBP230 million from the Royal Mail unit. This compares to profit of just GBP37 million a year ago, and would even exceed the GBP165 million posted for the same period in 2019.

At the other end of the large-caps, Entain was the worst performer, down 2.8%. The gambling firm was giving back some of its strong recent gains after it received a takeover approach from US peer DraftKings. The stock is up 22% this week alone.

Hargreaves Lansdown was down 2.0%, after the wealth manager's shares went ex-dividend, meaning new buyers no longer qualify for the latest payout.

GlaxoSmithKline was down 0.1% after Bloomberg reported on Wednesday that activist investor Bluebell Capital Partners has bought a stake in GlaxoSmithKline and criticised Chief Executive Officer Emma Walmsley.

In a letter seen by the news outlet, Bluebell called for a "thorough and robust process to identify the best (internal or external) candidate" to lead the company after it spins off its consumer division to focus on pharmaceuticals.

"The lack of Walmsley's industry knowledge was also very evident during the latest investor update," the letter said, echoing criticism from Elliott Investment Management.

Meanwhile, Marley Group confirmed its plans to list on London's Main Market, after saying earlier this month it was considering an initial public offering.

The Burton Upon Trent-based pitched roofing business did not disclose the number of shares to be issued, offer price or expected market capitalisation, but said it hopes to raise gross proceeds around GBP75 million. The IPO is likely to take place in October.

On the economic front, the UK private sector lost momentum in September with the rate of expansion in both output and new orders the weakest in seven months.

The IHS Markit-CIPS flash UK composite purchasing managers' index print was 54.1 points in September, below August's reading of 54.8.

The UK services PMI score was 54.6 points in September, down slightly from 55.0 in August and missed the market forecast, cited by FXStreet, of 55.0.

The UK manufacturing PMI reading was 56.3 points in September, sharply lower from 60.3 in August and missed the market estimate of 59.0.

All three UK PMI prints were the lowest seen in seven months.

"September's flash PMIs suggest that the economy is losing momentum a little faster than we originally anticipated, posing a downside risk to our view that the economy will return to its pre-pandemic level by November," commented analysts at Capital Economics.

The euro was priced at USD1.1715, down from USD1.1738.

A survey of eurozone business activity pointed to slower growth in September, Markit said, as bottlenecks curb activity and the input price gauge hit 21-year high. The flash headline composite purchasing managers' index fell sharply in September to 56.1 points from 59.0 points in August.

Any score above 50 represents growth, but the latest increase in business activity was the weakest since April, albeit still well above the survey's pre-pandemic long-run trend.

The flash services activity index read 56.3 points in September versus 59.0 points in August. The flash manufacturing output index fell back to 55.6 points in September from 59.0 points in August.

Against the Japanese yen, the dollar was trading at JPY109.87, up from JPY109.57.

Brent was quoted at USD75.94 a barrel Thursday at midday, higher against USD75.44 a barrel late Wednesday. Gold stood at USD1,771.22 an ounce, down from USD1,778.80.

US stock market futures were pointed to a higher open after the US Federal Reserve said the tapering of economic stimulus may "soon be warranted" as the economy edges closer to its employment and price stability goals.

The Dow Jones Industrial Average was called up 0.5%, the S&P 500 up 0.4%, and the Nasdaq Composite up 0.5%.

The Fed left its benchmark rate unchanged in the range of 0.00% to 0.25%. Chair Jerome Powell said the US economy has made progress towards the Fed's goals, and if things continue to advance at a speed that the Federal Reserve Open Market committee expects, a "moderation in the pace of asset purchases" may occur.

The Fed is currently buying at least USD80 billion in Treasury securities and USD40 billion in agency mortgage‑backed securities every month as part of its stimulus efforts.

Powell said that if the US economy continues to improve, "a gradual tapering process that concludes around the middle of next year is likely to be appropriate".

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.